C4 Therapeutics EBITDA Growth & History (CCCC)

C4 Therapeutics's calculated EBITDA was −$113.3M for fiscal 2025.

View full C4 Therapeutics company overview

C4 Therapeutics annual ebitda history

C4 Therapeutics annual ebitda

Fiscal yearPeriod endedEBITDAChangeGrowth
20252025-12-31−$113.3M$4.5M
20242024-12-31−$117.8M$19.4M
20232023-12-31−$137.2M−$9.3M
20222022-12-31−$127.9M−$47.2M
20212021-12-31−$80.6M−$21.8M
20202020-12-31−$58.8M−$25.0M
20192019-12-31−$33.9M

C4 Therapeutics ebitda trends

Over the last five reported fiscal years, C4 Therapeutics's ebitda decreased from −$58.8M to −$113.3M, a change of −$54.4M. The latest reported quarter, Q2 2026, shows −$26.1M.

About the metric

What EBITDA means

EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.

Calculation and source

How TickerStat calculates EBITDA

TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review C4 Therapeutics filings at SEC.gov ↗